Home > Healthcare > Pharmaceuticals > Finished Drug Form > Progesterone Market

Progesterone Market Size

  • Report ID: GMI8310
  • Published Date: Feb 2024
  • Report Format: PDF

Progesterone Market Size

Progesterone Market size was valued at USD 1.3 billion in 2023 and is estimated to grow at a CAGR of 12.7% between 2024 and 2032. High market growth can be attributed to the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis. For instance, as per the WHO, endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally.

 

 

Similarly, as per the Office on Women Health (OASH), more than 11% of American women between 15 and 44 are affected with endometriosis. Such high occurrence of hormone disorders is driving the demand for progesterone-based therapies. Additionally, rising incidences of infertility and the growing adoption of assisted reproductive technologies (ART) contribute significantly to the expansion of the market. Furthermore, the aging population worldwide, coupled with the rising prevalence of menopausal symptoms, fuels the demand for hormone replacement therapies (HRT).

Progesterone is a female hormone primarily produced by the ovaries, although it is also produced in smaller amounts by the adrenal glands and the placenta during pregnancy. It plays a crucial role in the menstrual cycle and in maintaining pregnancy.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of progesterone reached USD 1.3 billion in 2023 and is set to record 12.7% CAGR between 2024 and 2032, attributed to the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis.

The natural segment dominated the market with 58.2% share in 2023, because of its bio-identical nature that closely mimics the progesterone produced by the human body, making it a preferred choice for many patients seeking hormone replacement therapy.

North America market share was 39.2% of the revenue share in 2023, due to the region's advanced healthcare infrastructure, extensive R&D initiatives, and the widespread adoption of progesterone-based therapies for various medical conditions.

Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Cadila Pharmaceuticals, Cipla Inc., Estrellas Life Sciences Private Limited., Eli Lily & Company, Glenmark Pharmaceuticals Ltd., Insud Pharma S.L.U., Lupin, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.

Progesterone Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 353
  • Countries covered: 19
  • Pages: 210
 Download Free Sample